Introduction
============

Hormone dependence is a fundamental hallmark of the majority of breast cancers, and tumour growth can be inhibited either by deprivation of circulating oestrogens or by antagonising the effect of these hormones on their receptors \[[@B1]\]. The selective oestrogen receptor (ER) modulator tamoxifen has long been the most commonly used adjuvant therapy for patients with advanced hormone-sensitive breast cancer \[[@B2]\]. In recent years, however, aromatase inhibitors have become an alternative treatment option for postmenopausal women with breast cancer. An aromatase inhibitor acts by interfering with the enzyme that converts androgens to oestrogen, and reduces tumour and systemic oestrogen concentration \[[@B3]\]. The third-generation selective aromatase inhibitor anastrozole (Arimidex) reduces serum oestradiol to nanomolar concentrations \[[@B4]\]. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy of anastrozole alone or in combination with the established adjuvant treatment, tamoxifen for 5 years, as adjuvant treatment for postmenopausal women with operable breast cancer \[[@B5]\]. The study demonstrated that the efficacy of anastrozole was higher compared with tamoxifen alone, and also superior to the combination of both agents \[[@B5],[@B6]\]. After a median follow-up of 10 years, 5 years after completion of treatment, the significant advantage for anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal, ER-positive breast cancer patients was confirmed \[[@B7]\].

In breast cancer, genetic alterations such as amplifications and deletions occur within the tumour at high frequencies, and a number of these alterations are closely related to poor clinical outcome. One such region of amplification is 11q13, harbouring the cyclin D~1~gene *CCND1*\[[@B8]-[@B10]\]. Cyclin D~1~plays a crucial role as a cell cycle regulator, promoting progression through the G~1~-S phase, following complex formation with CDK4/6 and phosphorylation of the retinoblastoma protein \[[@B11]\]. Various studies have described the oncogenic capacity of cyclin D~1~*in vitro*, and overexpression *in vivo*results in tumour formation \[[@B12]-[@B14]\]. Overexpression of cyclin D~1~is observed in approximately 50% of breast cancers \[[@B15],[@B16]\], and cyclin D~1~is one of the most commonly overexpressed proteins in this form of cancer. A number of studies report cyclin D~1~overexpression to be a predictor of worse prognosis \[[@B17],[@B18]\], while others have found an association with an ER-positive phenotype and a better clinical outcome \[[@B19]-[@B23]\]. In about 15% of all primary breast cancers, overexpression is due to amplification of the corresponding gene *CCND1*\[[@B15],[@B24],[@B25]\], and this specific amplification has been linked to poor prognosis \[[@B23],[@B26]\].

Despite the presence of ERα, approximately 50% of breast cancers develop resistance to hormonal treatment, a major clinical limitation of breast cancer therapy \[[@B27],[@B28]\]. The mechanisms behind this phenomenon have been extensively studied, and imply a complex signalling network governing ER function and interaction with various co-regulators \[[@B29]-[@B32]\]. Cyclin D~1~is one such co-factor, known to interact with ERα and, independently of oestrogen, activate the receptor and potentially modify oestrogen/anti-oestrogen responses \[[@B33],[@B34]\]. Overexpression of cyclin D~1~has been reported to result in a conformational change in ERα that induces receptor activation in the presence of the novel selective ER modulator arzoxifene, which in turn promotes growth of MCF-7 cells - indicating a change from antagonist to agonist \[[@B28]\]. This study also suggests that different mechanisms are required to confer resistance depending on the specific anti-oestrogen administered, and that changes in the conformation of ERα play a crucial role in anti-hormonal insensitivity. A similar study demonstrated that overexpression of cyclin D~1~reversed the growth inhibitory effect of tamoxifen in two ER-positive breast cancer cell lines \[[@B35]\]. In line with these experimental findings we have previously observed that cyclin D~1~overexpression was associated with tamoxifen resistance in premenopausal and postmenopausal breast cancer \[[@B21],[@B36]\]. Worryingly, amplification of *CCND1*was further linked to a potentially detrimental effect of tamoxifen in premenopausal breast cancer patients, when compared with randomised control patients not receiving any adjuvant therapy \[[@B36]\].

The aim of our study was to characterise the association between *CCND1*amplification and cyclin D~1~protein expression and breast cancer recurrence in a large randomised cohort of postmenopausal patients with ER-positive breast cancer treated with endocrine therapy. In addition, we aimed to assess whether there was a significant difference in response to anastrozole versus tamoxifen according to cyclin D~1~gene and protein status, and thereby to address any potentially unfavourable effects of tamoxifen in subgroups of breast cancer defined by *CCND1*amplification.

Materials and methods
=====================

Patients
--------

The ATAC trial originally evaluated the efficacy and safety of 5 years of anastrozole, tamoxifen, or the combination of both treatments in postmenopausal patients presenting with localised breast cancer \[[@B7]\]. For the TransATAC protocol, formalin-fixed, paraffin-embedded blocks of the primary tumour were collected from as many hormone-receptor-positive patients as possible, from the monotherapy trial arms \[[@B37]\]. The endpoint for the analyses was any breast cancer recurrence and the median follow-up time was 10 years. The original study was performed according to the Declaration of Helsinki after approval by an institutional review board and ethics committee, and informed consent was obtained from all patients enrolled in the study.

Immunohistochemistry
--------------------

Nine tissue microarrays (TMAs) were used, each originally including from 165 to 200 tumour tissue samples from the patients included in the TransATAC study. This set of TMAs had one tissue core for each patient: a sample set was analysed for cyclin D~1~protein expression and a set was analysed for *CCND1*copy number. For detailed description of the TMA assembly we refer to our previously published study \[[@B37]\]. The TMA slides were deparaffinised, rehydrated and microwave-treated in target retrieval solution pH 9.9 (Dako, Glostrup, Denmark), and were processed in an automated immunostainer (Techmate 500; Dako, Copenhagen, Denmark) using the Envision software (Dako, Glostrup, Denmark). The antibody employed was a mouse monoclonal antibody reactive against human cyclin D~1~(1:100, clone DSC-6; Dako, Glostrup, Denmark).

Staining of cyclin D~1~was assessed as cytoplasmic staining intensity (0 to 2) as well as nuclear staining intensity (0 to 3) and fraction-positive nuclei (0, \< 1%, 1 to 9%, 10 to 32%, 33 to 67% and \> 67%) according to the Allred Score \[[@B38]\]. Evaluation was performed by two independent observers (one a pathologist), with the pathologist\'s score superseding the other observer\'s at consolidation. Conflicting observations were low (\< 5%) for all evaluations made. All immunohistochemical evaluations were performed without knowledge of tumour characteristics. In cases of no evaluation, the tumour cores were either nonrepresentative (that is, no invasive tumour cells) or were missing. This study was carried out and is reported according to REMARK guidelines \[[@B39]\].

Chromogenic *in situ*hybridisation
----------------------------------

Chromogenic *in situ*hybridisation (CISH) was performed according to the Zymed SPoT-Light Cyclin D~1~Probe protocol suited for CISH \[[@B40]\] using the SPoT-Light Cyclin D~1~Amplification Probe (Zymed Laboratories, Invitrogen Immunodetection, San Francisco, CA, USA). Pretreatment procedures included heating and enzyme digestion to optimise the CISH performance. Nonamplified cases were classified as 0, cases with up to 8 copies classified as 1 and \> 8 copies classified as 2. In statistical analyses, classifications 1 and 2 were both included in the subgroup defined as amplified.

Statistical analyses
--------------------

The primary endpoint for the analyses was time to recurrence (TTR), also known as the recurrence-free interval. TTR was defined as the time from randomisation to first locoregional recurrence, distant recurrence or contralateral disease. Statistical analyses were performed according to a prespecified statistical analysis plan approved by the ATAC Steering Committee. Cox proportional hazards regression models were fitted to TTR, and hazard ratios (HRs) and associated 95% confidence intervals (CIs) were estimated. The statistical tests employed for correlations between cyclin D~1~variables and clinicopathological parameters were the Armitage\'s trend test, the Wilcoxon test, the Goodman\'s test and the Cuzick test \[[@B41]\]. Multiple hypothesis testing was not corrected for, thus marginal *P*values should be interpreted with caution. The contribution of cyclin D~1~protein expression was analysed by the change in likelihood ratio chi-squared test (one degree of freedom) univariately and multivariately, in addition to a model with tumour size, nodal status, grade (central) and Ki67 expression, for all patients and nonamplified patients. All hypothesis tests were conducted at the two-sided *P*= 0.05 level. For detailed description of statistical analyses, we refer to a previous report \[[@B42]\].

Results
=======

Distribution of *CCND1*amplification status and cyclin D~1~protein staining categories
--------------------------------------------------------------------------------------

In the ATAC trial, 5,880 hormone-receptor-positive breast cancer patients were randomly assigned to receive the monotherapy anastrozole or tamoxifen. For the TransATAC protocol, 1,868 patients from the monotherapy arms were initially included. In the present study, 627 patients were not assessable for *CCND1*amplification status due to missing or damaged tissue cores, and 86 patients were excluded as they did not meet the study criteria of being ER-positive, leaving 1,155 patients assessable for *CCND1*amplification status. Out of the patients with known amplification status, 1,054 (91.3%) exhibited nonamplified tumours and 101 (8.7%) were amplified (Figure [1a](#F1){ref-type="fig"}). High cyclin D~1~cytoplasmic intensity was observed in 380 tumours (32.9%), high nuclear cyclin D~1~intensity in 278 tumours (24.1%), and 190 tumours (16.5%) had \> 67% nuclear fraction positivity as detailed in Additional file [1](#S1){ref-type="supplementary-material"}. *CCND1*gene amplification was associated with a higher expression of nuclear cyclin D~1~(*P*\< 0.001) as well as a higher fraction of positive nuclei (*P*\< 0.001), but was not significantly correlated to the amount of cytoplasmic protein (*P*= 0.063) (Table [1](#T1){ref-type="table"} and Figure [1b](#F1){ref-type="fig"}). Furthermore, positive correlations were observed between nuclear and cytoplasmic components of cyclin D~1~protein expression.

![**Chromogenic *in situ*hybridisation and immunohistochemical staining of breast cancer samples**. **(a)**Two copies of the *CCND1*gene represents nonamplified patients (i). A copy number of 3 to 8 copies was considered a gain (ii). Amplified tumours often exhibit a very high number of *CCND1*gene copies (iii). **(b)**Low cytoplasmic staining without nuclear cyclin D~1~expression (i). Low cyclin D~1~expression in cytoplasm and low fraction-positive nuclei displaying weak staining intensity of most nuclei (ii). Intermediate cytoplasmic expression and fraction-positive nuclei, with nuclei showing moderate staining intensity (iii). High cytoplasmic and nuclear expression of cyclin D~1~, with nuclear fraction \> 67% (iv).](bcr3161-1){#F1}

###### 

Associations between *CCND1*amplification status, cyclin D~1~protein expression and clinicopathological variables in all patients

  All patients                       Cyclin D~1~cytoplasmic intensity (negative/low, intermediate, high)   Cyclin D~1~nuclear intensity (negative/low, intermediate, high)   Cyclin D~1~nuclear fraction (\< 1%,1 to 9%, 10 to 32%, 33 to 67%, \> 67%)   Tumour grade (well, moderate, poor)   Tumour size^a^(mm)                Nodal status (negative, 1 to 3, \> 3)   Ki67^a^
  ---------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------- --------------------------------- --------------------------------------- --------------------------------
  *CCND1*amplification                                                                                                                                                                                                                                                                                                                                                   
   Nonamplified                      12%, 52%, 36%                                                         40%, 36%, 24%                                                     10%, 24%, 27%, 24%, 15%                                                     23%, 61%, 16%                         18.0                              70%, 23%, 7%                            4.0
   Amplified                         6%, 48%, 46%                                                          9%, 35%, 56%                                                      0%, 6%, 18%, 32%, 44%                                                       9%, 62%, 29%                          19.0                              64%, 26%, 10%                           7.5
                                     Armitage (*P*= 0.063)                                                 Armitage (*P*\< 0.001)                                            Armitage (*P*\< 0.001)                                                      Armitage (*P*\< 0.001)                Wilcoxon (*P*= 0.083)             Armitage (*P*= 0.341)                   Wilcoxon (*P*\< 0.001)
  Cyclin D~1~cytoplasmic intensity                                                                                                                                                                                                                                                                                                                                       
   Negative/low                                                                                            74%, 16%, 10%                                                     23%, 33%, 26%, 11%, 4%                                                      26%, 59%, 15%                         17.5                              68%, 24%, 8%                            3.2
   Intermediate                                                                                            40%, 36%, 24%                                                     10%, 24%, 27%, 25%, 14%                                                     17%, 63%, 20%                         19.0                              64%, 34%, 2%                            4.6
   High                                                                                                    20%, 43%, 37%                                                     3%, 16%, 25%, 28%, 28%                                                      23%, 61%, 16%                         17.0                              74%, 20%, 6%                            5.6
                                                                                                           Goodman = 0.44 (*P*\< 0.001)                                      Goodman = 0.39 (*P*\< 0.001)                                                Goodman = -0.06 (*P*= 0.238)          Cuzick trend (*P*= 0.010)         Goodman = -0.12 (*P*= 0.031)            Cuzick trend (*P*= 0.021)
  Cyclin D~1~nuclear intensity                                                                                                                                                                                                                                                                                                                                           
   Negative/low                                                                                                                                                              23%, 33%, 26%, 11%, 4%                                                      24%, 62%, 14%                         18.0                              67%, 25%, 8%                            2.9
   Intermediate                                                                                                                                                              1%, 12%, 41%, 36%, 10%                                                      18%, 65%, 17%                         18.0                              68%, 25%, 7%                            4.8
   High                                                                                                                                                                      0%, 1%, 7%, 37%, 55%                                                        17%, 59%, 24%                         17.5                              71%, 22%, 7%                            6.3
                                                                                                                                                                             Goodman = 0.88 (*P*\< 0.001)                                                Goodman = 0.16 (*P*\< 0.001)          Cuzick trend (*P*= 0.553)         Goodman = -0.05 (*P*= 0.327)            Cuzick trend (*P*\< 0.001)
  Cyclin D~1~nuclear fraction                                                                                                                                                                                                                                                                                                                                            
   \< 1%                                                                                                                                                                                                                                                 18%, 68%, 14%                         20.0                              2%, 29%, 9%                             2.8
   1 to 9%                                                                                                                                                                                                                                               23%, 62%, 15%                         18.0                              68%, 25%, 7%                            2.7
   10 to 32%                                                                                                                                                                                                                                             24%, 59%, 17%                         18.0                              71%, 25%, 4%                            4.4
   33 to 67%                                                                                                                                                                                                                                             20%, 59%, 21%                         18.0                              70%, 21%, 9%                            4.9
   \> 67%                                                                                                                                                                                                                                                12%, 68%, 20%                         16.0                              68%, 24%, 8%                            5.9
                                                                                                                                                                                                                                                         Cuzick trend (*P*= 0.005)             Spearman ρ = -0.04 (*P*= 0.162)   Cuzick trend (*P*= 0.694)               Spearman ρ = 0.22 (*P*\< 0.001

Tests used: Armitage\'s trend test, Wilcoxon test, Goodman\'s test, Spearman correlation test and Cuzick test. ^a^Median value for each category.

*CCND1*gene amplification and patient prognosis
-----------------------------------------------

Initially we studied the association between *CCND1*amplification status and TTR. Survival plots showed that patients exhibiting *CCND1*-amplified tumours had an increased risk of recurrence compared with patients showing nonamplified tumours (HR = 2.04; 95% CI, 1.37 to 3.03; χ~1~^2^= 10.51; *P*\< 0.001, univariate) (Figure [2a](#F2){ref-type="fig"}). Even when adjusting for the effects of tumour size, nodal status, grade (central) and Ki67 expression, amplification of *CCND1*was significantly associated with an increased risk of recurrence (HR = 1.61; 95% CI, 1.08 to 2.41; *P*= 0.03) (Table [2](#T2){ref-type="table"}).

![**Kaplan-Meier plots of recurrence risk over time in all patients**. **(a)**Risk of recurrence was increased for patients exhibiting *CCND1*-amplified breast cancers compared with nonamplified. **(b), (c)**No significant difference was observed between varying intensities of cytoplasmic or nuclear cyclin D~1~. **(d)**Patients showing a nuclear fraction of cyclin D~1~lower than 1% had an increased risk of recurrence compared with higher expression.](bcr3161-2){#F2}

###### 

Cox proportional Hazards models for estimating the effect on time to recurrence

                                                          Univariate                               Multivariate                 
  ------------------------------------------------------- --------------------- ------- ---------- --------------------- ------ -------
  All patients                                                                                                                  
   CCND1, amplified vs. nonamplified                      2.04 (1.37 to 3.03)   10.51   \< 0.001   1.61 (1.08 to 2.41)   4.86   0.030
   Cyclin D~1~cytoplasmic intensity, high vs. remainder   0.71 (0.51 to 0.98)   4.43    0.039      0.78 (0.56 to 1.09)   2.15   0.143
   Cyclin D~1~nuclear intensity, high vs. remainder       0.91 (0.64 to 1.28)   0.30    0.588      0.85 (0.59 to 1.21)   0.84   0.360
   Cyclin D~1~nuclear fraction, 1 to 100% vs. \< 1%       0.58 (0.38 to 0.90)   5.28    0.014      0.60 (0.39 to 0.92)   4.75   0.030
  Nonamplified patients                                                                                                         
   Cyclin D~1~cytoplasmic intensity, high vs. remainder   0.57 (0.39 to 0.82)   9.57    0.003      0.64 (0.44 to 0.95)   5.21   0.022
   Cyclin D~1~nuclear intensity, high vs. remainder       0.88 (0.60 to 1.32)   0.38    0.545      0.84 (0.55 to 1.26)   0.76   0.382
   Cyclin D~1~nuclear fraction, 1 to 100% vs. \< 1%       0.52 (0.34 to 0.81)   7.29    0.004      0.54 (0.35 to 0.85)   6.36   0.012

The χ~1~^2^value is based on the likelihood ratio test with the associated *P*values. Multivariate analyses were adjusted for tumour grade, tumour size, nodal status and Ki67. CI, confidence interval; HR, hazard ratio.

Cyclin D~1~protein expression and patient prognosis
---------------------------------------------------

We next investigated how cyclin D~1~protein localisation and expression was related to TTR. There was no significant difference in TTR with relation to cytoplasmic cyclin D~1~(Figure [2b](#F2){ref-type="fig"}) or cyclin D~1~nuclear intensity (Figure [2c](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Surprisingly, a greater fraction of cyclin D~1~-positive nuclei was associated with longer TTR (HR = 0.60; 95% CI, 0.39 to 0.92; *P*= 0.03) when adjusted for the effects of tumour size, nodal status, grade and Ki67 expression (Figures [2d](#F2){ref-type="fig"}, [3b](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Also, when subcategorising patients into high versus lower subgroups of cytoplasmic cyclin D~1~there was a trend towards a significant difference in TTR (*P*= 0.055; univariate, HR = 0.71; 95% CI, 0.51 to 0.98; *P*= 0.039) (Figure [3a](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}). When focusing on the non-amplified breast cancer samples, high cytoplasmic cyclin D~1~protein expression was indeed associated with a better outcome (*P*= 0.005) (Figure [3c](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}). The data further indicated that the lowest fraction of cyclin D~1~-positive nuclei (\< 1%) was associated with shorter TTR compared with subgroups of higher percentage positive nuclei, as illustrated in Figure [3b, d](#F3){ref-type="fig"}. Unfortunately, the number of *CCND1-*amplified cases was too low to analyse survival according to nuclear protein expression; that is, this subgroup contained no cases exhibiting a nuclear protein expression \< 1%.

![**Predicted risk of recurrence over time based on cytoplasmic intensity and nuclear fraction of cyclin D~1~, comparing two subgroups**. **(a)**In all patients, no significant difference in recurrence risk was observed between low and high cytoplasmic expression. **(b)**Patients showing a nuclear fraction of less than 1% positive cyclin D~1~nuclei had an increased risk of recurrence compared with a fraction of 1 to 100%, in all patients. **(c)**In patients exhibiting nonamplified tumours, high cytoplasmic expression was associated with a reduced risk of recurrence. **(d)**A fraction of cyclin D~1~-positive nuclei lower than 1% was associated with a higher recurrence risk also in patients showing nonamplified tumours.](bcr3161-3){#F3}

Interactions of cyclin D~1~and treatment, nodal status and Ki67
---------------------------------------------------------------

Based on previous reports indicating that amplification of the *CCND1*gene and cyclin D~1~overexpression might be associated with tamoxifen resistance or detrimental effects, we wanted to elucidate whether this could be further clarified in the patient cohort of the present study. The subgroup of patients treated with tamoxifen included 571 cases, and the anastrozole-treated subgroup included 584 patients. For *CCND1*amplification status there was no significant difference in TTR between anastrozole-treated and tamoxifen-treated patients (Figure [4a](#F4){ref-type="fig"}). Moreover, for nonamplified cases there was no difference according to nodal status or Ki67 levels between the treatment arms. For cytoplasmic cyclin D~1~expression there was an association in TTR according to amplification status (HR = 2.8; 95% CI, 1.2 to 6.4 for the interaction) (Figure [4b](#F4){ref-type="fig"}). In nonamplified breast cancers, however, no significant difference in TTR was observed for treatment (HR = 1.8; 95% CI, 0.8 to 3.9 for the interaction), nodal status (HR = 1.5; 95% CI, 0.7 to 3.2) or Ki67 levels (HR = 1.3; 95% CI, 0.6 to 3.0) (Figure [4b](#F4){ref-type="fig"}). Finally, for the nuclear fraction we observed an association in Ki67 levels for TTR (HR = 3.5; 95% CI, 1.0 to 12.3 for the interaction) (Figure [4c](#F4){ref-type="fig"}).

![**Forest plot showing the effect of *CCND1*amplification, cytoplasmic and nuclear cyclin D~1~expression**. **(a)**Amplified against nonamplified breast cancers in the subgroups of treatment, nodal status and Ki67. **(b)**High cytoplasmic intensity against low or intermediate intensity. **(c)**Nuclear fraction of 1 to 100% against \< 1% positive nuclei. Reference population for all subgroups was nonamplified patients (except for amplification status). HR, hazard ratio; neg, negative; pos, positive.](bcr3161-4){#F4}

Cyclin D~1~, *CCND1*and clinicopathological data
------------------------------------------------

The *CCND1*amplification status was positively correlated to tumour grade (*P*\< 0.001) and proliferation (defined as Ki67 expression) (*P*\< 0.001), but not to nodal status or tumour size (Table [1](#T1){ref-type="table"}). Cytoplasmic cyclin D~1~expression was inversely correlated to tumour size (all patients; *P*= 0.01) and nodal status (*P*= 0.031), and was positively correlated to proliferation (*P*= 0.021). Both nuclear staining intensity of cyclin D~1~and fraction-positive nuclei were associated with higher grade (*P*\< 0.001 and *P*= 0.005 respectively) and higher proliferation rate (both *P*\< 0.001).

Cyclin D~1~, proliferation and time to recurrence
-------------------------------------------------

Ki67 expression is a common marker used to analyse the proliferation rate in tumour samples, and high proliferation is linked to a more aggressive tumour phenotype. Surprisingly, despite a positive correlation between nuclear cyclin D~1~expression and Ki67 expression (Table [1](#T1){ref-type="table"} and Figure [5a](#F5){ref-type="fig"}), high expression of nuclear cyclin D~1~was associated with an improved TTR compared with low expression. To further illustrate how a combined proliferation and cyclin D~1~assessment would be linked to TTR we subdivided patients according to Ki67 expression and nuclear cyclin D~1~status. Patients with tumours exhibiting low Ki67 expression in association with 1 to 100% cyclin D~1~-positive nuclei (high) were associated with a considerably lower risk of recurrence (*P*\< 0.001) (Figure [5b](#F5){ref-type="fig"}) compared with the other subgroups. The subgroups of low cyclin D~1~include quite low patient numbers and hence the results should be interpreted with caution, but these results suggest that the expression of cyclin D~1~affects disease outcome independently of proliferation status.

![**Recurrence risk over time based on the expression of Ki67 and cyclin D~1~**. **(a)**Expression of Ki67 increased with increasing percentage of cyclin D~1~-positive nuclei in the breast tumours. **(b)**Kaplan-Meier plot showing that the combination of high Ki67 and low cyclin D~1~expression was associated with high risk of recurrence (green). Patients exhibiting a high fraction of cyclin D~1~-positive tumour cell nuclei in concurrence with low Ki67 expression showed the lowest risk of recurrence (red).](bcr3161-5){#F5}

Discussion
==========

Amplification of the *CCND1*gene has been associated with a poor patient outcome in previous studies \[[@B19],[@B26]\], whilst controversy regarding overexpression of cyclin D~1~protein in relation to patient survival still exists. Cyclin D~1~has been reported to be a prognostic marker in invasive breast cancer and has been associated with both a less aggressive ER-positive phenotype \[[@B20],[@B22]\] and also with an adverse clinical outcome \[[@B18]\]. These conflicting findings can potentially be explained by the low patient numbers analysed and/or methodological discrepancies. To clarify the importance of cyclin D~1~in breast cancer we therefore analysed the expression of cyclin D~1~in different subcellular localisations, using a previously validated antibody \[[@B36]\], as well as the gene amplification status by the well-established CISH technique in a large, well-characterised randomised patient cohort including more than 1,000 patients with ER-positive breast cancers. Our data support studies indicating that low cyclin D~1~protein expression as well as *CCND1*amplification are linked to tumour aggressiveness and increased risk of disease recurrence in ER-positive postmenopausal breast cancer \[[@B23],[@B26]\]. Similar findings have been observed for HER2, where both high expression linked to amplification and low expression are linked to poor outcome \[[@B43]\].

Amplification of *CCND1*was observed in 8.7% of the tumours, which is slightly lower than the frequency of 10 to 15% generally reported, even though some groups have demonstrated a lower percentage of *CCND1*-amplified tumours \[[@B15],[@B44],[@B45]\]. The slightly lower fraction of *CCND1*-amplified cases may be due to all patients being ER-positive or due to methodological differences and different cutoff points for defining amplification between studies. In addition, the use of TMAs has certain limitations; however, this technique is indispensable when analysing large patient materials and is today a well-accepted approach for large-scale tumour sample analysis. In agreement with previous studies, gene amplification of *CCND1*was associated with an overall adverse clinical outcome. The observed positive correlation between nuclear cyclin D~1~expression and tumour grade and proliferation suggests a link between cyclin D~1~and aggressive disease. In contrast, both higher nuclear expression and high cytoplasmic expression of cyclin D~1~was instead associated with a decreased recurrence risk. Despite a positive association between cyclin D~1~protein and *CCND1*amplification status, both low nuclear fraction of cyclin D~1~and *CCND1*amplification were linked to earlier disease recurrence independently of other clinicopathological parameters - hence both factors serve as prognostic markers in endocrine-treated, ER-positive postmenopausal breast cancer. In patients not displaying *CCND1*amplification, cytoplasmic expression of cyclin D~1~was also an independent marker for longer TTR, indicating that the true prognostic value of cyclin D~1~protein expression may be obscured by the *CCND1*-amplified cases: the clinicopathological significance of cyclin D~1~expression might thus be best considered separately for amplified and nonamplified cases.

Apart from the role as a prognostic marker, cyclin D~1~has been proposed as a predictive factor for tamoxifen response, as illustrated by poor clinical outcome in patients with ER-positive tumours with high cyclin D~1~expression treated with tamoxifen \[[@B46]\]. These findings together with numerous experimental reports \[[@B33]-[@B35]\] support that cyclin D~1~overexpression might abrogate the response to tamoxifen, as previously reported by our group and others \[[@B21],[@B46]\]. Our earlier discoveries have nevertheless been made in cohorts where patients were randomly assigned to receive either no adjuvant treatment or to receive tamoxifen \[[@B21],[@B36]\]. In the present study we compared the two endocrine therapies anastrozole and tamoxifen in relation to disease recurrence and cyclin D~1~status, but there were no untreated control patients. There was no significant difference in treatment response between these two adjuvant therapies by stratification for cyclin D~1~status, indicating that cyclin D~1~is not a predictive marker for differences in response to anastrozole versus tamoxifen. No conclusions can be drawn, however, regarding cyclin D~1~as a marker for general endocrine treatment resistance, since no untreated patients were available for analysis within the TransATAC study. Moreover, differences in tamoxifen response in relation to cyclin D~1~in postmenopausal versus premenopausal breast cancer might exist. Our previous study reporting a potential unfavourable effect of tamoxifen included premenopausal patients exclusively, whereas this study focused exclusively on postmenopausal breast cancer cases and has shown no detrimental effect since the results for the two endocrine therapies were similar.

The relationship between cyclin D~1~, proliferation and prognosis is quite complex, with a positive correlation between cyclin D~1~and Ki67 - Ki67 is associated with shorter TTR, while cyclin D~1~is associated with longer TTR. Patients showing low expression of Ki67 had a longer TTR with the highest levels of cyclin D~1~expression, whereas patients exhibiting higher levels of Ki67 had the shortest TTR with the lowest levels of cyclin D~1~expression. Multivariate analysis identified the fraction cyclin D~1~-positive nuclei as a predictor of outcome independently of other clinicopathological parameters such as Ki67. These results suggest that, irrespective of proliferation status, intermediate to high expression of cyclin D~1~results in a prolonged TTR in ER-positive, postmenopausal breast cancer patients. Similar results were observed in our previous study of randomised material from premenopausal breast cancer patients \[[@B47]\]. The relationship between cyclin D~1~, proliferation and prognosis hence seems to be complex, and this could in part be explained by potential additional functions for cyclin D~1~unrelated to proliferation control, as well as co-amplification and co-deletion of specific genes on chromosome 11q13, the locus harbouring *CCND1*.

Conclusions
===========

This study confirms that the cyclin D~1~status provides independent prognostic information regarding ER-positive, postmenopausal breast cancers, supporting its emerging role as a biomarker that might be useful in the clinic. Our results demonstrate that high expression of cyclin D~1~was associated with a reduced risk of recurrences, whereas amplification of the *CCND1*gene was linked to an aggressive disease. Finally, no difference in response to anastrozole compared with tamoxifen was observed according to expression of cyclin D~1~gene amplification or protein expression.
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